Novel mode of action of polybia-MPI, a novel antimicrobial peptide, in multi-drug resistant leukemic cells

doi:10.1016/j.canlet.2008.12.027

CORC > 兰州大学 > 兰州大学 > 基础医学院 > 期刊论文

	Novel mode of action of polybia-MPI, a novel antimicrobial peptide, in multi-drug resistant leukemic cells
	Wang, KR; Yan, JX; Zhang, BZ; Song, JJ; Jia, PF; Wang, R; Wang, R (reprint author), Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, State Key Lab Chinese Med & Mol Pharmacol, Hong Kong, Hong Kong, Peoples R China.
刊名	CANCER LETTERS
	2009-06-08
卷号	278 期号:1 页码:65-72
关键词	Polybia-MPI Selective toxicity Plasma membrane perturbation Necrosis Multi-drug resistant
ISSN号	0304-3835
DOI	10.1016/j.canlet.2008.12.027
文献子类	Article
英文摘要	As the frequent emergency of resistant tumor cells during treatment, the development of new agents with new modes of action attracts a great deal of interest. Polybia-MPI was a short cationic alpha-helical amphiphilic peptide that has selective toxicity toward cancer cells but no hemolytic activity. Its target selectivity is based on the binding preference to membranes containing anionic phospholipids by electrostatic driving. Its ability to make PI and trypan blue permeate into tumor cells at the same rate (within minutes), suggests a killing mechanism that involves plasma membrane perturbation. SEM and confocal microscopy experiments verified that the cell died as a result of acute injury and bursting, suggesting necrosis. As compared to the conventional chemotherapy, polybia-MPI targets at the cell membrane rather than enters into the cell to exert its action. So it is difficult for tumor cells to develop resistance to polybia-MPI during treatment and its action is not affected by the common multi-drug resistant mechanism. Although this is an initial study that looked at its in vitro activity rather than the in vivo activity, with the increasing resistance of conventional chemotherapy, polybia-MPI may offer a novel therapeutic strategy in the treatment of multi-drug resistant cancer. (c) 2009 Published by Elsevier Ireland Ltd.
学科主题	Oncology
出版地	CLARE
资助项目	国家自然科学基金项目 ; 长江学者和创新团队发展计划 ; 高等学校博士学科点专项科研基金 ; 中央高校基本科研业务费专项资金
项目编号	National Natural Science Foundation of China [20525206, 20621091, 20772052, 90813012] ; Specialized Research Fund for the Doctoral Program in Higher Education Institutions [20070730052, 20060730017] ; Changjiang Scholar Program of the Ministry of Education of China ; Interdisciplinary Innovation Research Fund for Young Scholars, Lanzhou University [LZU200509]
语种	英语
WOS记录号	WOS:000265712800010
资助机构	NSFC ; MOE ; LZU
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/121407]
专题	基础医学院_期刊论文
通讯作者	Wang, R (reprint author), Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, State Key Lab Chinese Med & Mol Pharmacol, Hong Kong, Hong Kong, Peoples R China.
推荐引用方式 GB/T 7714	Wang, KR,Yan, JX,Zhang, BZ,et al. Novel mode of action of polybia-MPI, a novel antimicrobial peptide, in multi-drug resistant leukemic cells[J]. CANCER LETTERS,2009,278(1):65-72.
APA	Wang, KR.,Yan, JX.,Zhang, BZ.,Song, JJ.,Jia, PF.,...&Wang, R .(2009).Novel mode of action of polybia-MPI, a novel antimicrobial peptide, in multi-drug resistant leukemic cells.CANCER LETTERS,278(1),65-72.
MLA	Wang, KR,et al."Novel mode of action of polybia-MPI, a novel antimicrobial peptide, in multi-drug resistant leukemic cells".CANCER LETTERS 278.1(2009):65-72.